Assay News and Research

RSS

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard- against the human papillomavirus, which causes cervical cancer. The research will evaluate the efficacy of Carraguard- - a clear gel made from the seaweed derivative carrageenan - in preventing new HPV infections in women.

26 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan Corporation, plc today reported its second quarter and first half 2010 financial results.

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Replacing hydrogen with deuterium increases stability, shelf life of fluorescent probes: Research

By swapping out one specific hydrogen atom for an isotope twice as heavy, researchers have increased the shelf life and detection ability of fluorescent probes that are essential to studying a variety of inflammatory diseases, including cancer and atherosclerosis. The probes detect and measure reactive oxygen species, which play an important role in disease processes.

21 Jul 2010

Patent application for inexpensive CyPath assay filed by Biomoda

Cancer diagnostics company Biomoda,filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

21 Jul 2010

Affymetrix introduces Axiom Custom Genotyping Arrays

Affymetrix, Inc. today announced that it has launched Axiom™ Custom Genotyping Arrays, the newest addition to the Axiom Genotyping Solution. Researchers can now leverage Affymetrix' Axiom Genomic Database, the world's largest collection of validated common and rare SNPs, to create custom arrays containing 50,000 to as many as 2.6 million SNPs. This inherent flexibility allows researchers to conduct genome-wide association, replication, fine mapping, and candidate gene studies on a single platform.

21 Jul 2010

SDIX announces multi-year collaboration with Banyan Biomarkers

SDIX, today announced a multi-year collaboration with Banyan Biomarkers, Inc. to provide products and services for Banyan's biomarker discovery work in the detection of traumatic brain injury.

20 Jul 2010

Cellectis bioresearch introduces new technology to develop cell-based assays for HTS studies

Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis, today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS).The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving cell-based assays for HTS studies than classical methods.

20 Jul 2010

Bionas launches new Bionas adcon reader for impedance-based, cellular analysis

Bionas GmbH announces the launch of its new Bionas® adcon reader for impedance-based, cellular analysis. The Bionas adcon reader technology is based on real-time monitoring of cellular impedance, thus giving real-time data about cell adhesion, membrane integrity, cellular morphology and cell proliferation for applications in toxicology, oncology, receptor signaling as well as the quality management of cells.

19 Jul 2010

Scientists awarded $2.3M grant to develop new treatments for drug addiction

A pair of scientists on the Florida campus of The Scripps Research Institute has been awarded a $2.3 million grant by the National Institutes of Health to conduct research relevant to developing new treatments for drug addiction.

15 Jul 2010

NanoString Technologies increases throughput of nCounter Analysis System

NanoString Technologies, Inc., a privately held life sciences company marketing a novel digital molecular barcoding technology for detecting and counting large sets of targets in biological samples, today announced that it has increased the throughput of its nCounter Analysis System by expanding its multiplexing capacity to 800 gene transcripts per reaction.

From NanoString Technologies 15 Jul 2010

ZyGEM launches new microbial fingerprinting diagnostic technology

ZyGEM Corp. Ltd., has introduced its new microbial fingerprinting diagnostic technology that is expected to dramatically reduce the complexity and time needed to identify unknown infectious agents in mixed population samples. The approach is designed to run on the company's new MicroLab platform and has the potential to accurately identify up to 30 types of microbes simultaneously from a single sample in less than an hour.

14 Jul 2010

InQ Biosciences to launch fully integrated Cell Research System

InQ Biosciences, a provider of innovative technologies for cell growth and research, announced its plans to launch the InQ™ Cell Research System during the fourth quarter of 2010. InQ is the first fully integrated system that creates a high fidelity in vivo environment for studying stem cells, plus nerve, brain, and other mammalian cells for disease research.

14 Jul 2010

Universal surveillance for MRSA decreased HAIs related to devices: Study

Pitt County Memorial Hospital today announced results of a study demonstrating that universal surveillance for methicillin-resistant Staphylococcus aureus decreased health care-associated infections related to devices. Infection rates decreased 68 percent for ventilator-associated pneumonias; 51 percent for central line-associated bacteremias; and 49 percent for catheter-associated urinary tract infections.

14 Jul 2010

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

14 Jul 2010

FDA clears Meridian Bioscience's new illumigene C. difficile molecular amplification assay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its new molecular amplification assay, illumigene™ C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon.

14 Jul 2010

Palex to distribute MDI's Detect-Ready MRSA assay in Spain

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Palex Medical S.A., one of Spain's leading distributors of medical device and diagnostic products to hospitals, today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready™ MRSA assay in Spain.

13 Jul 2010

Roche obtains global co-exclusive license for PI3K biomarker from QIAGEN

Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN's wholly owned subsidiary DxS, now QIAGEN Manchester.

From QIAGEN Manchester Limited 13 Jul 2010

Amorfix Life Sciences uses A(4) test to detect accumulation of Abeta in mouse models of AD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases including Alzheimer's disease, has used its A(4) test to compare the rate of accumulation of aggregated Abeta in the brain tissue of various mouse models of AD. Amorfix presented this new data at the International Conference on Alzheimer's Disease this week.

13 Jul 2010